The Flair trial represents a substantial advancement in the treatment of chronic lymphocytic leukaemia (CLL), presenting a chemotherapy-free option that has demonstrated remarkable efficacy. Conducted across 96 cancer centers in the UK and involving 786 patients, it assessed the effectiveness of two targeted drugs, ibrutinib and venetoclax, compared to standard chemotherapy. Results revealed that 94% of patients on the combined treatment were alive and free from disease progression after five years, with additional evidence showing better tolerability and less severe side effects than traditional therapies. Experts herald this trial as a potential turning point in CLL treatment.
The Flair trial is a landmark study that demonstrates a chemotherapy-free approach can lead to better patient outcomes, showcasing the efficacy of targeted cancer drugs.
After five years, 94% of patients receiving the combined treatment of ibrutinib and venetoclax were alive and disease-free, highlighting its potential over traditional chemotherapy.
Collection
[
|
...
]